A blended education program designed by Springer Healthcare IME, in collaboration with Dr Paul Cornes, for all medical oncologists, specialist nurses and allied healthcare professionals (HCPs) working with patients for whom biosimilars may represent a treatment option.
Despite their promise, the uptake, and therefore benefits, of biosimilars in oncology has been slower than expected. A key barrier to their uptake is low HCP knowledge and acceptance of the concept of biosimilarity. Despite an increase in medical education, there are several clinical and non-clinical factors that contribute to a lack of confidence among HCPs.
This program aims to provide HCPs with a better understanding of the biosimilar development process and extrapolation of indications concept, and to help improve their confidence in prescribing biosimilars to their patients. Our goal is to focus on the key issues from the HCP point of view in order to support them in resolving and overcoming these barriers.